MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Viking Therapeutics Inc

Cerrado

SectorSalud

25.68 7.67

Resumen

Variación precio

24h

Actual

Mínimo

23.51

Máximo

25.74

Métricas clave

By Trading Economics

Ingresos

-10M

-35M

BPA

-0.32

Empleados

36

EBITDA

-9.6M

-46M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+319.28% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-375M

2.9B

Apertura anterior

18.01

Cierre anterior

25.68

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Viking Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23 dic 2024, 15:04 UTC

Principales Noticias

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dic 2024, 14:53 UTC

Principales Noticias

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4 nov 2024, 12:22 UTC

Principales Noticias

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4 nov 2024, 12:00 UTC

Principales Noticias

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4 nov 2024, 10:11 UTC

Acciones populares

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4 oct 2024, 12:01 UTC

Principales Noticias

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 oct 2024, 12:01 UTC

Principales Noticias

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20 sept 2024, 13:55 UTC

Principales Noticias

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25 jul 2024, 15:03 UTC

Ganancias

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Comparación entre iguales

Cambio de precio

Viking Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

319.28% repunte

Estimación a 12 meses

Media 100.25 USD  319.28%

Máximo 164 USD

Mínimo 38 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Viking Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

15

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.09Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

180 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.